Spero Therapeutics (SPRO) Other Operating Expenses (2022 - 2025)
Spero Therapeutics posted quarterly Other Operating Expenses of $587000.0 for Q3 2025, down 88.94% on a QoQ basis from $5.3 million in Q3 2023.
Spero Therapeutics (SPRO) has 3 years of Other Operating Expenses data on file, last reported at $587000.0 in Q3 2025.
- For the quarter ending Q3 2025, Other Operating Expenses changed N/A year-over-year to $587000.0; the trailing twelve-month figure through Mar 2026 stood at $587000.0 (changed N/A YoY), and the FY2025 full-year result was $587000.0, changed N/A from the prior year.
- Other Operating Expenses for Q3 2025 stood at $587000.0, down from $5.3 million in the prior quarter.
- Across five years, Other Operating Expenses topped out at $8.6 million in Q4 2022 and bottomed at $587000.0 in Q3 2025.
- The 3-year median for Other Operating Expenses is $5.3 million (2023), against an average of $4.8 million.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 587,000.00 |
| Sep 30, 2023 | 5.31 Mn |
| Dec 31, 2022 | 8.55 Mn |